Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy's: More excitement in store - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Aug 1, 2001

    Dr. Reddy's: More excitement in store

    Dr. Reddy has recorded a 115% growth in net profit for 1QFY02, much in line with market expectations. The figures for the current quarter is on a consolidated basis with Cheminor drugs and American Remedies. To provide meaningful comparison, previous quarter numbers are also on a consolidated basis. International formulations sales and a breakthrough in generic business contributed to the surge in net profit. Sales growth was driven primarily by 89% growth in branded formulations exports. Domestic branded formulations grew by 21%, outsmarting the industry growth rates.

    (Rs m) 1QFY01* 1QFY02* % change
    Sales 2,146 2838 32.2%
    Other Income 71 86 21.0%
    Expenditure 1,737 2185 25.8%
    Operating Profit (EBDIT) 409 654 59.6%
    Operating Profit Margin (%) 19.1% 23.0%  
    Interest 114 50 -56.1%
    Depreciation 85 112 31.1%
    Profit before Tax 281 577 105.3%
    Tax 32 42 31.6%
    Profit after Tax/(Loss) 249 535 114.7%
    Net profit margin (%) 11.6% 18.9%
    No. of Shares (eoy) (m) 38.2 38.2  
    Fully Diluted Earnings per share* 26.1 56.0  
    P/E (at current price) 30.2  
    (**- annualised)      
    (*- Consolidated)      

    Operating margins registered a healthy increase of 390 basis points on the back of higher-margin formulation exports and a significant breakthrough in the US generics market. The margins in the US generics market are more than 50%. Savings in interest cost also contributed significantly to net profit growth. Dr. Reddy's utilised US$ 69 m from net ADR proceeds of US$ 124 m to repay its debt, which is in line with the ADR utilisation projections.

    In a related development, the company cleared the final hurdle for launching 40 mg fluoxetine (generic of Eli Lilly's block buster product Prozac) in the US markets with a six month marketing exclusivity. Dr.Reddy's would be the first Indian company to receive such exclusivity which ensures very high margins for its products. The company expects to launch the product in first week of August.

    At the current market of Rs 1,690, the stock trades at a P/e of 30x the annualised earnings for 1QFY02. . The company has also been quick in deploying its ADR funds, which removes concerns for a considerable drop in RoCE. The highlights of the first quarter results is the significant breakthrough in the US generics market. The windfall gains from fluoxetine exclusivity is expected to be the key earnings driver in the coming quarters (approximately the company is expected to earn US$ 16 m from marketing). Other valuation triggers for the stock at this point of time are probable acquisitions (the company has reserved US$ 78 m towards this), windfall gains from research pipeline and other breakthrough's in the generic market.. However, any negative news from R&D front or delay in lauching products for the generics market could lead to a fall in valuations as the markets have built lot of expectations from the company.

    Dr. Reddy's has decided to go for stock split in the ratio of 2:1.



    Equitymaster requests your view! Post a comment on "Dr. Reddy's: More excitement in store ". Click here!


    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts